Glutamatergic Mechanisms of Psychosis and Target Engagement (SA1)
Status:
Recruiting
Trial end date:
2023-02-01
Target enrollment:
Participant gender:
Summary
50 healthy volunteers (HV) will participate in 2 identical ketamine-induced pharmacoBOLD
(phBOLD) sessions at least 7 days apart. On both days, clinical assessments will be performed
following removal of the subject from the scanner.
HV will be discharged home after clearance by the study physician. This study will assign
ketamine doses in successive 10 subject cohorts. The ketamine dose for the 1st cohort will
start at 0.08 mg/kg. For subsequent cohorts, the bolus will be successively reduced or
increased by 0.02 mg/kg (n=10/dose) to determine the lowest dose of ketamine that still
produces a robust phBOLD response.
The study will be subject and rater blind, i.e. subjects and raters, will be blinded to the
treatment (ketamine dose) group.
The study physician will be aware of the ketamine dose, and ketamine dose will be the same
for both sessions.
Subjects will not be told what the exact ketamine dose they will receive, but it will be
based on their weight and will be no higher than 0.08 mg/kg.